Kiran Mazumdar-Shaw, executive chairperson of Biocon on Tuesday said rising input and logistics costs could weigh heavily on the pharma market.Speaking at the IBLA Jury – Navigating 2022, she said, "I think inflation is also something that will add to healthcare costs. So we need to find a balancing measure to see how we can address these issues. Otherwise, we are going to see inflationary trends in terms of our products and services."Also Read: Indian economy has recovered 'handsomely' from pandemic-induced disruptions: PanagariyaTalking about the country's pharma spend, Mazumdar-Shaw said, "I certainly would like India to move up from 4 percent of the value capture of the global pharma market to upwards of 15 at least percent. To do that we have to move into innovation big time."On innovation and R&D in the Indian pharma market, she said the country needs to improve, "I have been engaging with the government to see if we can follow the PLI scheme with a research-linked incentive scheme. So I do think we need more fund flows in R&D and we need incentives for people to seriously invest in innovation.""When I look at healthcare and pharma sector, I am very optimistic as the world attention has focused on increasing healthcare spends and to that effect, the pharma sector is going to benefit," Biocon chief said.Also Read: EXPLAINER: Why are oil prices high, and any relief in sight?